There are presently no approved drug therapies for ROP in the U.S. VEGF inhibitors are often used off-label to treat the disease but have potential safety concerns because of adverse effects on the developing retina and brain in neonates [2,3,7,8,9,10,11,16,17,18]. Here, VEGFA is linked to retinopathy of prematurity.